SI3191081T1 - Formulacija, ki vsebuje glikopirolat, postopek in naprava - Google Patents

Formulacija, ki vsebuje glikopirolat, postopek in naprava

Info

Publication number
SI3191081T1
SI3191081T1 SI201531220T SI201531220T SI3191081T1 SI 3191081 T1 SI3191081 T1 SI 3191081T1 SI 201531220 T SI201531220 T SI 201531220T SI 201531220 T SI201531220 T SI 201531220T SI 3191081 T1 SI3191081 T1 SI 3191081T1
Authority
SI
Slovenia
Prior art keywords
glycopyrrolate
formulation
Prior art date
Application number
SI201531220T
Other languages
English (en)
Inventor
Fergus Manford
Original Assignee
Vectura Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51542160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3191081(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vectura Limited filed Critical Vectura Limited
Publication of SI3191081T1 publication Critical patent/SI3191081T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SI201531220T 2014-09-09 2015-09-09 Formulacija, ki vsebuje glikopirolat, postopek in naprava SI3191081T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14184164 2014-09-09
PCT/EP2015/070660 WO2016038116A1 (en) 2014-09-09 2015-09-09 Formulation comprising glycopyrrolate, method and apparatus
EP15762595.5A EP3191081B1 (en) 2014-09-09 2015-09-09 Formulation comprising glycopyrrolate, method and apparatus

Publications (1)

Publication Number Publication Date
SI3191081T1 true SI3191081T1 (sl) 2020-07-31

Family

ID=51542160

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201531220T SI3191081T1 (sl) 2014-09-09 2015-09-09 Formulacija, ki vsebuje glikopirolat, postopek in naprava

Country Status (38)

Country Link
US (2) US10532041B2 (sl)
EP (2) EP3689332A1 (sl)
JP (1) JP6502501B2 (sl)
KR (1) KR101927960B1 (sl)
CN (1) CN106604720B (sl)
AP (1) AP2017009777A0 (sl)
AR (1) AR101793A1 (sl)
AU (1) AU2015314272B2 (sl)
BR (1) BR112017003888B1 (sl)
CA (1) CA2960694C (sl)
CL (1) CL2017000560A1 (sl)
CO (1) CO2017003056A2 (sl)
CY (1) CY1124569T1 (sl)
DK (1) DK3191081T3 (sl)
DO (1) DOP2017000065A (sl)
EA (1) EA037332B1 (sl)
EC (1) ECSP17021465A (sl)
ES (1) ES2793905T3 (sl)
HR (1) HRP20201005T1 (sl)
HU (1) HUE049339T2 (sl)
IL (1) IL250427A0 (sl)
LT (1) LT3191081T (sl)
MA (2) MA50680A (sl)
MX (1) MX2017003080A (sl)
MY (1) MY181647A (sl)
NZ (1) NZ728435A (sl)
PH (1) PH12017500303B1 (sl)
PL (1) PL3191081T3 (sl)
PT (1) PT3191081T (sl)
RS (1) RS60299B1 (sl)
SG (1) SG11201700536XA (sl)
SI (1) SI3191081T1 (sl)
SV (1) SV2017005403A (sl)
TN (1) TN2017000077A1 (sl)
TW (1) TWI602566B (sl)
UA (1) UA115958C2 (sl)
WO (1) WO2016038116A1 (sl)
ZA (1) ZA201700658B (sl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11219602B2 (en) 2017-03-15 2022-01-11 Vectura Limited Method for making a micronized dry powder formulation of glycopyrrolate and magnesium stearate
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
CN116194087A (zh) * 2020-01-15 2023-05-30 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9808470D0 (en) 1998-04-22 1998-06-17 Smithkline Beecham Plc Novel process and apparatus
GB9826284D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826286D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
CA2404645A1 (en) 2000-04-11 2001-10-18 Elan Pharmaceuticals, Inc. Physically stabilized dry powder formulations
AU2001289708A1 (en) 2000-07-20 2002-02-05 Campina B.V. Method for producing a crystalline tableting additive, additive thus obtained and use thereof
AU2211502A (en) 2000-11-30 2002-06-11 Vectura Ltd Method of making particles for use in a pharmaceutical composition
GB0030074D0 (en) 2000-12-08 2001-01-24 Univ London Pharmacy Particulate inhalation carrier
DE10212264A1 (de) 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
US7309707B2 (en) 2002-03-20 2007-12-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
ITMI20022674A1 (it) 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US7188993B1 (en) * 2003-01-27 2007-03-13 Harold W Howe Apparatus and method for resonant-vibratory mixing
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
JO3102B1 (ar) 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0410398D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20060292077A1 (en) 2005-03-18 2006-12-28 Zhao Jonathon Z Dendritic and star-shaped contrast agents for medical devices and bioabsorbable radiopaque bulk material and method for producing same
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
JP2009500163A (ja) 2005-07-07 2009-01-08 ナノセラピューティクス・インコーポレイテッド 粉末を製粉および調製する方法及びそれにより得られる組成物
GB0523654D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
JP5283835B2 (ja) * 2006-07-06 2013-09-04 東京エレクトロン株式会社 マイクロ波プラズマ処理装置及びマイクロ波プラズマ処理装置用ゲートバルブ
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
EP1944018A1 (en) 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
WO2009061273A1 (en) 2007-11-07 2009-05-14 Astrazeneca Ab Dry powder formulations comprising ascorbic acid derivates
PL2234595T3 (pl) 2007-12-13 2013-04-30 Novartis Ag Sposób zmniejszania tendencji soli glikopironiowej do agregacji podczas składowania
RU2496479C2 (ru) 2007-12-13 2013-10-27 Новартис Аг Органические соединения
US8235314B2 (en) 2009-02-12 2012-08-07 Linde Aktiengesellschaft Nonequilibrium humidity control for jet milling
PT2417106T (pt) 2009-04-09 2017-02-13 Novartis Ag Processo para preparação de sais de pirrolidínio
NZ595902A (en) 2009-04-24 2014-10-31 Iceutica Pty Ltd Method for the production of commercial nanoparticle and microparticle powders
ES2675575T3 (es) * 2010-04-01 2018-07-11 Chiesi Farmaceutici S.P.A. Proceso para preparar partículas vehículo para polvos secos para inhalación
WO2011131663A1 (en) 2010-04-21 2011-10-27 Chiesi Farmaceutici S.P.A. "process for providing particles with reduced electrostatic charges"
US20130157991A1 (en) 2010-08-31 2013-06-20 Osama Ahmed Aswania Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties and Methods of Administering the Same
EP2749283A3 (en) 2011-02-17 2014-08-20 Cipla Limited Combination of glycopyrronium and olodaterol
JO3510B1 (ar) 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
CN103687483A (zh) 2011-05-17 2014-03-26 珍珠治疗公司 用于呼吸递送两种或多种活性剂的组合物、方法和系统
GB201205632D0 (en) 2012-03-30 2012-05-16 Vectura Ltd Method and apparatus
WO2014007766A1 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhalers comprising a carrier other than lactose
EA201590030A1 (ru) 2012-07-05 2015-09-30 Арвен Айлак Санайи Ве Тиджарет А.С. Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы, и третий компонент
DE102012211907A1 (de) * 2012-07-09 2014-01-09 Robert Bosch Gmbh Drehschlagschrauber mit einem Schlagwerk
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
JP2016519160A (ja) 2013-05-22 2016-06-30 パール セラピューティクス，インコーポレイテッド ３つ以上の活性薬剤を呼吸性送達するための組成物、方法、及びシステム
US20160317391A1 (en) 2013-12-17 2016-11-03 Merck Sharp & Dohme Corp. Media milling process for the manufacture of active pharmaceutical ingredients in propellants

Also Published As

Publication number Publication date
CN106604720A (zh) 2017-04-26
PH12017500303A1 (en) 2017-07-03
UA115958C2 (uk) 2018-01-10
JP2017527621A (ja) 2017-09-21
CO2017003056A2 (es) 2017-07-11
KR20170054458A (ko) 2017-05-17
JP6502501B2 (ja) 2019-04-17
MX2017003080A (es) 2017-11-15
IL250427A0 (en) 2017-03-30
ECSP17021465A (es) 2017-05-31
AP2017009777A0 (en) 2017-03-31
AU2015314272A1 (en) 2017-02-09
BR112017003888A2 (pt) 2018-01-23
US20200155506A1 (en) 2020-05-21
DK3191081T3 (da) 2020-06-15
EA037332B1 (ru) 2021-03-15
HUE049339T2 (hu) 2020-09-28
HRP20201005T1 (hr) 2020-10-16
MY181647A (en) 2020-12-30
BR112017003888B1 (pt) 2022-11-16
CY1124569T1 (el) 2022-03-24
WO2016038116A1 (en) 2016-03-17
CA2960694C (en) 2021-05-04
PT3191081T (pt) 2020-05-29
SG11201700536XA (en) 2017-02-27
DOP2017000065A (es) 2017-07-15
ES2793905T3 (es) 2020-11-17
US10532041B2 (en) 2020-01-14
KR101927960B1 (ko) 2018-12-11
NZ728435A (en) 2017-11-24
EP3689332A1 (en) 2020-08-05
TN2017000077A1 (en) 2018-07-04
TW201617072A (zh) 2016-05-16
CN106604720B (zh) 2020-03-10
EP3191081A1 (en) 2017-07-19
MA50680A (fr) 2020-08-05
TWI602566B (zh) 2017-10-21
PL3191081T3 (pl) 2020-09-07
EA201790544A1 (ru) 2017-09-29
LT3191081T (lt) 2020-07-10
CA2960694A1 (en) 2016-03-17
RS60299B1 (sr) 2020-07-31
AU2015314272B2 (en) 2017-11-23
CL2017000560A1 (es) 2018-03-16
MA40617B1 (fr) 2020-05-29
EP3191081B1 (en) 2020-03-25
PH12017500303B1 (en) 2017-07-03
MA40617A (fr) 2017-07-19
ZA201700658B (en) 2022-05-25
US20170258762A1 (en) 2017-09-14
SV2017005403A (es) 2017-08-23
AR101793A1 (es) 2017-01-11

Similar Documents

Publication Publication Date Title
ZA201606392B (en) Mobile sterilization apparatus and method for using the same
SG10201406577PA (en) Method, apparatus, and program
HK1244388A1 (zh) 方法、裝置和系統
GB201409086D0 (en) Apparatus and method
GB201409077D0 (en) Apparatus and method
GB201409064D0 (en) Method and apparatus
SG10201408403VA (en) Evaluation method, and evaluation apparatus
GB201405662D0 (en) Apparatus and method
PT3210417T (pt) Método e aparelho para adquirir informações de sistema
SG11201703087WA (en) Communication apparatus and communication method
GB201417624D0 (en) Apparatus, system and method
ZA201603217B (en) Apparatus, program, and method
GB201406332D0 (en) Apparatus and method
IL250427A0 (en) Formulations containing glycopyrrolate, method and standard
EP3104659A4 (en) Apparatus and method
EP3119120A4 (en) Apparatus and method
GB201407801D0 (en) Apparatus and method
EP3188526A4 (en) Apparatus and method
EP3151527A4 (en) Apparatus and method
GB201414572D0 (en) Apparatus, System and Method
GB201411726D0 (en) Apparatus and method
GB201411631D0 (en) Apparatus and method
GB201405663D0 (en) Apparatus and method
GB201413236D0 (en) Method and apparatus
GB201412726D0 (en) Method and apparatus